Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on
Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
SEATTLE, Dec. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTAX: CTIC) management to hold a conference call tomorrow
(Thursday, December 27) at 8:30 am EST to discuss update on Zevalin asset
purchase, CMS reimbursement, and PIX301 timing for results.
Conference Call Numbers
Thursday, December 27
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific
800-218-0204
303-262-2130
Webcast available at
http://www.cticseattle.com -
webcast will be archived approximately two hours after call ends.
Call-back numbers for post listening available at 10:00 am Eastern
800-405-2236
303-590-3000
Passcode: 11105647
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
Susan Callahan
T: 206.272.4472
F: 206.272.4434
E: media@ctiseattle.com
http://www.cticseattle.com/media.htm
Investors Contact:
Leah Grant
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
http://www.cticseattle.com/investors.htm
SOURCE Cell Therapeutics, Inc.
media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200, or Susan Callahan,
+1-206-272-4472, fax, +1-206-272-4434, media@ctiseattle.com, or investors,
Leah Grant, +1-206-282-7100, fax, +1-206-272-4434, invest@ctiseattle.com, all
of Cell Therapeutics, Inc.
